• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

了解大麻素受体结构状态的动力学以及不同调节剂的作用。

Understanding the Dynamics of the Structural States of Cannabinoid Receptors and the Role of Different Modulators.

作者信息

Manandhar Anjela, Haron Mona H, Klein Michael L, Elokely Khaled

机构信息

Institute for Computational Molecular Science and Department of Chemistry, Temple University, Philadelphia, PA 19122, USA.

National Center for Natural Products Research, University of Mississippi, Oxford, MS 38677, USA.

出版信息

Life (Basel). 2022 Dec 18;12(12):2137. doi: 10.3390/life12122137.

DOI:10.3390/life12122137
PMID:36556502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9786085/
Abstract

The cannabinoid receptors CBR and CBR are members of the G protein-coupled receptor (GPCR) family. These receptors have recently come to light as possible therapeutic targets for conditions affecting the central nervous system. However, because CBR is known to have psychoactive side effects, its potential as a drug target is constrained. Therefore, targeting CBR has become the primary focus of recent research. Using various molecular modeling studies, we analyzed the active, inactive, and intermediate states of both CBRs in this study. We conducted in-depth research on the binding properties of various groups of cannabinoid modulators, including agonists, antagonists, and inverse agonists, with all of the different conformational states of the CBRs. The binding effects of these modulators were studied on various CB structural features, including the movement of the transmembrane helices, the volume of the binding cavity, the internal fluids, and the important GPCR properties. Then, using in vitro experiments and computational modeling, we investigated how vitamin E functions as a lipid modulator to influence THC binding. This comparative examination of modulator binding to CBRs provides significant insight into the mechanisms of structural alterations and ligand affinity, which can directly help in the rational design of selective modulators that target either CBR or CBR.

摘要

大麻素受体CBR和CBR是G蛋白偶联受体(GPCR)家族的成员。这些受体最近作为影响中枢神经系统疾病的潜在治疗靶点而受到关注。然而,由于已知CBR具有精神活性副作用,其作为药物靶点的潜力受到限制。因此,靶向CBR已成为近期研究的主要焦点。在本研究中,我们使用各种分子建模研究分析了两种CBR的活性、非活性和中间状态。我们对包括激动剂、拮抗剂和反向激动剂在内的各类大麻素调节剂与CBR所有不同构象状态的结合特性进行了深入研究。研究了这些调节剂对各种CB结构特征的结合作用,包括跨膜螺旋的移动、结合腔的体积、内部流体以及重要的GPCR特性。然后,通过体外实验和计算建模,我们研究了维生素E作为脂质调节剂如何影响THC结合。这种对调节剂与CBR结合的比较研究为结构改变和配体亲和力机制提供了重要见解,这可以直接有助于合理设计靶向CBR或CBR的选择性调节剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/6ef8175827ed/life-12-02137-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/09e020b9b497/life-12-02137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/bb30c5f447ed/life-12-02137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/7fc59df8cbbb/life-12-02137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/8a72a4d14550/life-12-02137-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/ec466acde6a2/life-12-02137-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/e5ead44e825d/life-12-02137-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/6d9f232e5bea/life-12-02137-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/c148608908d8/life-12-02137-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/9766d2edf311/life-12-02137-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/6ef8175827ed/life-12-02137-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/09e020b9b497/life-12-02137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/bb30c5f447ed/life-12-02137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/7fc59df8cbbb/life-12-02137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/8a72a4d14550/life-12-02137-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/ec466acde6a2/life-12-02137-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/e5ead44e825d/life-12-02137-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/6d9f232e5bea/life-12-02137-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/c148608908d8/life-12-02137-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/9766d2edf311/life-12-02137-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9776/9786085/6ef8175827ed/life-12-02137-g010.jpg

相似文献

1
Understanding the Dynamics of the Structural States of Cannabinoid Receptors and the Role of Different Modulators.了解大麻素受体结构状态的动力学以及不同调节剂的作用。
Life (Basel). 2022 Dec 18;12(12):2137. doi: 10.3390/life12122137.
2
Elucidation of partial activation of cannabinoid receptor type 2 and identification of potential partial agonists: Molecular dynamics simulation and structure-based virtual screening.阐明大麻素受体 2 的部分激活作用,并鉴定潜在的部分激动剂:基于分子动力学模拟和结构的虚拟筛选。
Comput Biol Chem. 2022 Aug;99:107723. doi: 10.1016/j.compbiolchem.2022.107723. Epub 2022 Jul 6.
3
Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.从植物化合物中鉴定新型大麻素 CB2 受体激动剂及其抗骨质疏松作用的初步评价。
Molecules. 2022 Jan 21;27(3):702. doi: 10.3390/molecules27030702.
4
Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.配体辅助蛋白质结构(LAPS):一种用于表征大麻素受体配体结合结构域的实验范式。
Methods Enzymol. 2017;593:217-235. doi: 10.1016/bs.mie.2017.06.022. Epub 2017 Jul 3.
5
CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.CB1 和 CB2 受体是他莫昔芬和 4OH-他莫昔芬的新型分子靶标。
Biochem Biophys Res Commun. 2013 Nov 15;441(2):339-43. doi: 10.1016/j.bbrc.2013.10.057. Epub 2013 Oct 19.
6
Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.绘制大麻素1受体变构位点:新型、强效且不可逆结合探针GAT100的关键分子决定因素和信号特征
ACS Chem Neurosci. 2016 Jun 15;7(6):776-98. doi: 10.1021/acschemneuro.6b00041. Epub 2016 Apr 25.
7
Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.利用变构作用来改善 G 蛋白偶联受体 (GPCR) 导向治疗药物:大麻素受体 1 作为发现靶标。
Expert Opin Drug Discov. 2016 Dec;11(12):1223-1237. doi: 10.1080/17460441.2016.1245289. Epub 2016 Oct 21.
8
Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.AM3677的分子相互作用和信号转导特征,一种对大麻素1受体具有选择性的新型共价激动剂。
ACS Chem Neurosci. 2015 Aug 19;6(8):1400-10. doi: 10.1021/acschemneuro.5b00090. Epub 2015 May 29.
9
Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?大麻素受体作为自身免疫性疾病的治疗靶点:我们处于什么位置?
Drug Discov Today. 2019 Sep;24(9):1845-1853. doi: 10.1016/j.drudis.2019.05.023. Epub 2019 May 31.
10
Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development.描述表达于尤因肉瘤 TC-71 和 A-673 细胞中的大麻素受体,作为抗癌药物开发的潜在靶点。
Life Sci. 2021 Nov 15;285:119993. doi: 10.1016/j.lfs.2021.119993. Epub 2021 Sep 28.

引用本文的文献

1
Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1.针对大麻素受体CB1的FDA批准化合物的计算和实验性药物重新利用
Pharmaceuticals (Basel). 2023 Dec 2;16(12):1678. doi: 10.3390/ph16121678.

本文引用的文献

1
Distinct activation mechanisms regulate subtype selectivity of Cannabinoid receptors.不同的激活机制调节大麻素受体的亚型选择性。
Commun Biol. 2023 May 5;6(1):485. doi: 10.1038/s42003-023-04868-1.
2
Potential Pro-Inflammatory Effect of Vitamin E Analogs through Mitigation of Tetrahydrocannabinol (THC) Binding to the Cannabinoid 2 Receptor.维生素 E 类似物通过减轻四氢大麻酚(THC)与大麻素 2 受体结合而产生潜在的促炎作用。
Int J Mol Sci. 2022 Apr 13;23(8):4291. doi: 10.3390/ijms23084291.
3
Mechanistic origin of partial agonism of tetrahydrocannabinol for cannabinoid receptors.
四氢大麻酚对大麻素受体部分激动作用的机制起源。
J Biol Chem. 2022 Apr;298(4):101764. doi: 10.1016/j.jbc.2022.101764. Epub 2022 Feb 26.
4
GPCR activation mechanisms across classes and macro/microscales.跨类和宏/微观尺度的 G 蛋白偶联受体激活机制。
Nat Struct Mol Biol. 2021 Nov;28(11):879-888. doi: 10.1038/s41594-021-00674-7. Epub 2021 Nov 10.
5
Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI.支气管肺泡灌洗液中维生素 E 醋酸酯与 EVALI 相关。
N Engl J Med. 2020 Feb 20;382(8):697-705. doi: 10.1056/NEJMoa1916433. Epub 2019 Dec 20.
6
Selective modulation of the cannabinoid type 1 (CB) receptor as an emerging platform for the treatment of neuropathic pain.对1型大麻素(CB)受体的选择性调节作为治疗神经性疼痛的新兴平台。
Medchemcomm. 2019 Mar 18;10(5):647-659. doi: 10.1039/c8md00595h. eCollection 2019 May 1.
7
Revealing the Mechanism of Agonist-Mediated Cannabinoid Receptor 1 (CB1) Activation and Phospholipid-Mediated Allosteric Modulation.揭示激动剂介导的大麻素受体 1(CB1)激活和磷脂介导的变构调节的机制。
J Med Chem. 2019 Jun 13;62(11):5638-5654. doi: 10.1021/acs.jmedchem.9b00612. Epub 2019 May 29.
8
Structural Insights into CB1 Receptor Biased Signaling.结构洞察大麻素 CB1 受体偏向信号传导。
Int J Mol Sci. 2019 Apr 13;20(8):1837. doi: 10.3390/ijms20081837.
9
Crystal Structure of the Human Cannabinoid Receptor CB2.人源大麻素受体 CB2 的晶体结构
Cell. 2019 Jan 24;176(3):459-467.e13. doi: 10.1016/j.cell.2018.12.011. Epub 2019 Jan 10.
10
Advances in patented CB1 receptor antagonists for obesity.用于治疗肥胖症的专利CB1受体拮抗剂的进展。
Pharm Pat Anal. 2018 Sep;7(5):169-173. doi: 10.4155/ppa-2018-0020. Epub 2018 Aug 1.